000 02367 a2200625 4500
005 20250517222316.0
264 0 _c20181108
008 201811s 0 0 eng d
022 _a1873-264X
024 7 _a10.1016/j.jpba.2018.05.052
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aReis, Rafael
245 0 0 _aLiquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
_h[electronic resource]
260 _bJournal of pharmaceutical and biomedical analysis
_cSep 2018
300 _a174-183 p.
_bdigital
500 _aPublication Type: Journal Article; Validation Study
650 0 4 _aAcrylamides
650 0 4 _aAfatinib
650 0 4 _aAniline Compounds
650 0 4 _aAntineoplastic Agents
_xblood
650 0 4 _aCarcinoma, Non-Small-Cell Lung
_xblood
650 0 4 _aChromatography, High Pressure Liquid
650 0 4 _aCrizotinib
650 0 4 _aDrug Monitoring
_xmethods
650 0 4 _aDrug Stability
650 0 4 _aErbB Receptors
_xantagonists & inhibitors
650 0 4 _aErlotinib Hydrochloride
_xblood
650 0 4 _aHumans
650 0 4 _aIndoles
_xblood
650 0 4 _aLimit of Detection
650 0 4 _aLung Neoplasms
_xblood
650 0 4 _aPiperazines
_xblood
650 0 4 _aProtein Kinase Inhibitors
_xblood
650 0 4 _aPyrazoles
_xblood
650 0 4 _aPyridines
_xblood
650 0 4 _aQuinazolines
_xblood
650 0 4 _aReceptors, Vascular Endothelial Growth Factor
_xantagonists & inhibitors
650 0 4 _aReproducibility of Results
650 0 4 _aSensitivity and Specificity
650 0 4 _aTandem Mass Spectrometry
700 1 _aLabat, Laurence
700 1 _aAllard, Marie
700 1 _aBoudou-Rouquette, Pascaline
700 1 _aChapron, Jeanne
700 1 _aBellesoeur, Audrey
700 1 _aThomas-Schoemann, Audrey
700 1 _aArrondeau, Jennifer
700 1 _aGiraud, Frédérique
700 1 _aAlexandre, Jérôme
700 1 _aVidal, Michel
700 1 _aGoldwasser, François
700 1 _aBlanchet, Benoît
773 0 _tJournal of pharmaceutical and biomedical analysis
_gvol. 158
_gp. 174-183
856 4 0 _uhttps://doi.org/10.1016/j.jpba.2018.05.052
_zAvailable from publisher's website
999 _c28511976
_d28511976